Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 830 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Cancer in My Community: The Roadblocks to Receiving Cancer Care in... September 23, 2021 March is Multiple Myeloma Action Month March 29, 2022 Ensuring a Smooth Leadership Transition at NCI April 10, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Trastuzumab Deruxtecan Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa Lucky 13-A Male Breast Cancer Story Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal...
